Sadie Roberts

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Martin Kaiser, Andrew Hall, Katrina Walker et al. · Journal of Clinical Oncology · 2023 · 110 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

Sarah Brown, Debbie Sherratt, Samantha Hinsley et al. · BMJ Open · 2021 · 27 citations · Full text

Medicine, Hematology, Oncology +14

Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma

Mihaela Rata, Matthew Blackledge, Erica Scurr et al. · Insights into Imaging · 2022 · 23 citations · Full text

Medicine, Oncology, Radiology +17

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.

Martin Kaiser, Andrew Hall, Katrina Walker et al. · Journal of Clinical Oncology · 2021 · 17 citations

Medicine, Hematology, Oncology +11

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Holger W. Auner, Sarah Brown, Katrina Walker et al. · Blood Cancer Journal · 2022 · 15 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16